Author: Dr. Maciej Czerwinski
New FDA Draft Guidance “Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics” – XenoTech’s perspective on in vitro DDI testing
The FDA has released a new draft guidance for industry titled “Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics.”...
XenoTech Joins Fight Against Liver Disease
XenoTech is committed to furthering the knowledge surrounding hepatic diseases, such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis...
Drug-Drug Interaction (DDI) Prediction Models Following In Vitro Studies in Preclinical Development
In preclinical development, a drug will be evaluated for potential to cause a drug-drug interaction (DDI) using in vitro experiments and then calculations that...
Can Interactions Between Therapeutic Proteins and Small Molecule Drugs Be Evaluated In Vitro?
The mechanisms of clearance for small molecule drugs and therapeutic proteins are fundamentally distinct and therefore therapeutic proteins are generally not...
New Liver Tissue Microarrays Available – What Would Benefit Your Research?
As technology evolves to better meet needs in exploration of drug metabolism pathways and disease mechanisms, familiarization with appropriate and...
New Liver Disease Resource and Other Research Biobank News
XenoTech is committed to furthering the knowledge surrounding hepatic diseases, which affects one out of four people worldwide, such as...
Subscribe to our Newsletter
Stay up to date with our news, events and research
Do you have a question or a request for upcoming blog content?
We love to get your feedback
